Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are ...

As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is ...

Sanofi (EPA:SAN – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of €99.37 ($106.85) and traded as high as €103.28 ...

Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of ...

As part of the Fast Track designation, Sanofi is set to launch a Phase I/II trial to evaluate the immunogenicity and safety of its novel mRNA vaccine in preventing chlamydia.

Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...

Sanofi is adding a new contender, agreeing to pay $600 million for a bispecific drug with an approach that could be first in class. The sum announced Thursday is an upfront payment for Dren Bio ...

Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu ...

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last ...